Nls Pharmaceutics Ag Stock Buy Hold or Sell Recommendation
| NLSP Stock | USD 0.14 0.01 7.69% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding NLS Pharmaceutics AG is 'Strong Sell'. Macroaxis provides NLS Pharmaceutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NLSP positions. The advice algorithm takes into account all of NLS Pharmaceutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting NLS Pharmaceutics' buy or sell advice are summarized below:
Real Value 2.54 | Target Price 9.75 | Hype Value 0.11 | Market Value 0.14 | Naive Value 0.11 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell NLS Pharmaceutics AG given historical horizon and risk tolerance towards NLS Pharmaceutics. When Macroaxis issues a 'buy' or 'sell' recommendation for NLS Pharmaceutics AG, the advice is generated through an automated system that utilizes algorithms and statistical models.
NLS |
Execute NLS Pharmaceutics Buy or Sell Advice
The NLS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NLS Pharmaceutics AG. Macroaxis does not own or have any residual interests in NLS Pharmaceutics AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NLS Pharmaceutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
NLS Pharmaceutics Trading Alerts and Improvement Suggestions
| NLS Pharmaceutics generated a negative expected return over the last 90 days | |
| NLS Pharmaceutics has high historical volatility and very poor performance | |
| NLS Pharmaceutics has some characteristics of a very speculative penny stock | |
| NLS Pharmaceutics has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 354.34 K in liabilities. NLS Pharmaceutics has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist NLS Pharmaceutics until it has trouble settling it off, either with new capital or with free cash flow. So, NLS Pharmaceutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NLS Pharmaceutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NLS to invest in growth at high rates of return. When we think about NLS Pharmaceutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (16.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG currently holds about 1.35 M in cash with (13.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| NLS Pharmaceutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from seekingalpha.com: NLS Pharmaceutics receives Nasdaq staff delisting determination |
NLS Pharmaceutics Returns Distribution Density
The distribution of NLS Pharmaceutics' historical returns is an attempt to chart the uncertainty of NLS Pharmaceutics' future price movements. The chart of the probability distribution of NLS Pharmaceutics daily returns describes the distribution of returns around its average expected value. We use NLS Pharmaceutics AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NLS Pharmaceutics returns is essential to provide solid investment advice for NLS Pharmaceutics.
| Mean Return | -1.51 | Value At Risk | -10.81 | Potential Upside | 7.69 | Standard Deviation | 6.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NLS Pharmaceutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
NLS Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NLS Pharmaceutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NLS Pharmaceutics AG backward and forwards among themselves. NLS Pharmaceutics' institutional investor refers to the entity that pools money to purchase NLS Pharmaceutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2023-12-31 | 56.5 K | Geode Capital Management, Llc | 2023-12-31 | 14.4 K | Renaissance Technologies Corp | 2023-12-31 | 12.7 K | Bank Of America Corp | 2023-12-31 | 90.0 | Affinity Asset Advisors, Llc | 2023-12-31 | 0.0 | J. Goldman & Co Lp | 2023-12-31 | 0.0 |
NLS Pharmaceutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 41.1K | 0.0 | 13.5K | 21.8K | 25.1K | 16.8K | |
| Change In Cash | 213.6K | (126.6K) | 5.3M | 3.5M | 4.0M | 4.2M | |
| Net Borrowings | 557.9K | 667.7K | 1.2M | (2.1M) | (1.9M) | (1.8M) | |
| Free Cash Flow | (190.0K) | (729.4K) | (15.0M) | (13.9M) | (12.5M) | (11.9M) | |
| Other Non Cash Items | 1.1M | (72.1M) | 166.5K | 364.6K | 328.2K | 344.6K | |
| Net Income | (5.4M) | (2.9M) | (11.9M) | (16.5M) | (14.8M) | (14.1M) | |
| End Period Cash Flow | 220.3K | 93.7K | 5.4M | 8.9M | 10.3M | 10.8M | |
| Change To Netincome | 655.8K | 385.0K | (4.3K) | 124.9K | 112.4K | 201.1K |
NLS Pharmaceutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NLS Pharmaceutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NLS Pharmaceutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NLS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -1.44 | |
β | Beta against NYSE Composite | -1.17 | |
σ | Overall volatility | 6.97 | |
Ir | Information ratio | -0.23 |
NLS Pharmaceutics Volatility Alert
NLS Pharmaceutics AG is displaying above-average volatility over the selected time horizon. NLS Pharmaceutics AG is a potential penny stock. Although NLS Pharmaceutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in NLS Pharmaceutics AG. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on NLS instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.NLS Pharmaceutics Fundamentals Vs Peers
Comparing NLS Pharmaceutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NLS Pharmaceutics' direct or indirect competition across all of the common fundamentals between NLS Pharmaceutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as NLS Pharmaceutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NLS Pharmaceutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing NLS Pharmaceutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NLS Pharmaceutics to competition |
| Fundamentals | NLS Pharmaceutics | Peer Average |
| Return On Equity | -8.63 | -0.31 |
| Return On Asset | -4.14 | -0.14 |
| Current Valuation | 2.82 M | 16.62 B |
| Shares Outstanding | 43.32 M | 571.82 M |
| Shares Owned By Insiders | 31.54 % | 10.09 % |
| Shares Owned By Institutions | 23.83 % | 39.21 % |
| Number Of Shares Shorted | 75.11 K | 4.71 M |
| Price To Book | 4.84 X | 9.51 X |
| EBITDA | (15.47 M) | 3.9 B |
| Net Income | (16.5 M) | 570.98 M |
| Cash And Equivalents | 1.35 M | 2.7 B |
| Cash Per Share | 0.08 X | 5.01 X |
| Total Debt | 354.34 K | 5.32 B |
| Current Ratio | 0.59 X | 2.16 X |
| Book Value Per Share | (0.13) X | 1.93 K |
| Cash Flow From Operations | (13.88 M) | 971.22 M |
| Short Ratio | 0.05 X | 4.00 X |
| Earnings Per Share | (0.50) X | 3.12 X |
| Target Price | 6.0 | |
| Beta | -0.84 | -0.15 |
| Market Capitalization | 5.98 M | 19.03 B |
| Total Asset | 9.28 M | 29.47 B |
| Retained Earnings | (58.2 M) | 9.33 B |
| Working Capital | 5.89 M | 1.48 B |
| Net Asset | 9.28 M |
NLS Pharmaceutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NLS . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About NLS Pharmaceutics Buy or Sell Advice
When is the right time to buy or sell NLS Pharmaceutics AG? Buying financial instruments such as NLS Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2023 | 2024 (projected) | Short and Long Term Debt Total | 1.9M | 1.8M | Total Assets | 10.7M | 11.2M |
Use Investing Ideas to Build Portfolios
In addition to having NLS Pharmaceutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Dividend Beast Thematic Idea Now
Dividend Beast
An experimental equal-weighted theme of equities with high dividend yield and solid fundamentals based on Macroaxis rating system. The Dividend Beast theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Dividend Beast Theme or any other thematic opportunities.
| View All Next | Launch |
Check out NLS Pharmaceutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for NLS Stock analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is NLS Pharmaceutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NLS Pharmaceutics. If investors know NLS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NLS Pharmaceutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.50) | Return On Assets (4.14) | Return On Equity (8.63) |
The market value of NLS Pharmaceutics is measured differently than its book value, which is the value of NLS that is recorded on the company's balance sheet. Investors also form their own opinion of NLS Pharmaceutics' value that differs from its market value or its book value, called intrinsic value, which is NLS Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NLS Pharmaceutics' market value can be influenced by many factors that don't directly affect NLS Pharmaceutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NLS Pharmaceutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NLS Pharmaceutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NLS Pharmaceutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.